Oxybutynin Chloride Tablet
Product Images NDC 43063-931

7 FDA label images from Pd-rx Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 43063-931). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

43063931 Label (43063931)

43063931 Label (43063931)
Label for Oxybutynin Chloride USP 5 mg oral tablets, supplied in a bottle of 30 tablets. The label includes the NDC 43063-931-30 and states the product is manufactured by PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK. It contains dosing instructions blank, warning about drowsiness, and safety warnings for keeping out of reach of children, with expiration date 11/2020 and lot number G19E59.*
FDA Label Image

Structural Formula (Figure 1 Structure)

Structural Formula (Figure 1 Structure)
Chemical structure diagram representing the active ingredient oxybutynin chloride. The structure includes aromatic, cyclohexyl, ester, alkyne, and amine functional groups consistent with oxybutynin chloride's molecular composition.*
FDA Label Image

Table 1 (Figure 2 Table1)

Table 1 (Figure 2 Table1)
A data table comparing pharmacokinetic parameters of R-Oxybutynin and S-Oxybutynin, including Cmax (ng/mL), Tmax (hours), AUCt (ng·h/mL), and AUCinf (ng·h/mL), with mean values and standard deviations shown for each parameter.*
FDA Label Image

Figure 1 (Figure 3 Figure1)

Figure 1 (Figure 3 Figure1)
A line graph showing mean plasma oxybutynin concentration (ng/mL) over 24 hours after oral administration of Oxybutynin 5 mg three times daily (TID). The x-axis represents time in hours, and the y-axis shows plasma concentration levels with error bars indicating variability at each time point.*
FDA Label Image

Table 2 (Figure 4 Table2)

Table 2 (Figure 4 Table2)
A data table comparing pharmacokinetic parameters of R-Oxybutynin, S-Oxybutynin, R-Desethyloxybutynin, and S-Desethyloxybutynin. The table includes Cmax (ng/mL), Tmax (hr), and AUC (ng*hr/mL) values with mean and standard deviation, reflecting pooled data for each compound.*
FDA Label Image

Figure 2 (Figure 5 Figure2)

Figure 2 (Figure 5 Figure2)
A line graph showing mean plasma concentration of R-oxybutynin over time in hours. The y-axis represents concentration in ng/mL, ranging from 0 to 10, and the x-axis shows time points from 0 to 12 hours. Data points include error bars indicating variability at each time interval.*
FDA Label Image

Table 3 (Figure 6 Table3)

Table 3 (Figure 6 Table3)
A data table listing adverse events by body system for Oxybutynin Chloride administered at 5-20 mg/day in a sample of 199 patients. It details the frequency percentages of adverse events such as urinary tract infection, insomnia, nervousness, dizziness, blurred vision, dry mouth, constipation, and urinary retention.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.